Deep-Vein Thrombosis Clinical Trial
Official title:
Protocol CV185017: A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Deep-Vein Thrombosis
The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or fondaparinux and vitamin K antagonist in the treatment of subjects with acute symptomatic deep-vein thrombosis.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00245856 -
Treatment of Upper Extremity Deep-Vein Thrombosis
|
Phase 4 | |
| Withdrawn |
NCT01602432 -
Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients
|
||
| Completed |
NCT01602445 -
Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism
|
N/A | |
| Completed |
NCT00314990 -
VITRO-Trial. B Vitamins and the Secondary Prevention of Venous Thrombosis
|
N/A |